Azacitidine-associated haemorrhagic enteritis in a case of myelodysplastic syndrome: A case report.
J Clin Pharm Ther
; 45(4): 828-831, 2020 Aug.
Article
en En
| MEDLINE
| ID: mdl-32436280
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE:
5-Azacitidine (AZA) is an agent widely used to treat myelodysplastic syndrome (MDS). CASE DESCRIPTION We herein report an 83-year-old woman diagnosed with MDS who was treated with AZA. She tolerated the first cycle of AZA; however, severe adverse events involving haemorrhagic enteritis with multiple intestinal ulcers developed after the second and third cycles. Additionally, the interval between the administration of AZA and the development of haematochezia shortened with each cycle of AZA. WHAT IS NEW ANDCONCLUSION:
We herein report as-yet-undescribed potential side effects, AZA-associated haemorrhagic enteritis that should be kept in mind.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Azacitidina
/
Síndromes Mielodisplásicos
/
Enteritis
/
Hemorragia Gastrointestinal
Límite:
Aged80
/
Female
/
Humans
Idioma:
En
Revista:
J Clin Pharm Ther
Asunto de la revista:
FARMACIA
/
TERAPEUTICA
Año:
2020
Tipo del documento:
Article
País de afiliación:
Japón